EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

Jennifer A Chan, Susan Geyer, Tyler Zemla, Michael V Knopp, Spencer Behr, Sydney Pulsipher, Fang-Shu Ou, Amylou C Dueck iD, Jared Acoba, Ardaman Shergill, Edward M Wolin, Thorvardur R Halfdanarson und 12 weitere

New England Journal of Medicine · 13.02.2025 · 392 (7) · 653-665

DOI: 10.1056/nejmoa2403991 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 13.02.2025. Verfasst von Jennifer A Chan und 23 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neuroendocrine Tumors, Pancreatic Neoplasms, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 175-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Exelixis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeuroendocrine TumorsPancreatic NeoplasmsTyrosine Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDouble-Blind MethodKaplan-Meier EstimateProgression-Free SurvivalHypertensionFatigueDiarrheaThromboembolismNeoplasm GradingTreatment OutcomeAnilidesPyridines

Substanzen

Antineoplastic AgentscabozantinibTyrosine Kinase InhibitorsAnilidesPyridines

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston.
  • Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.
  • Wright Center of Innovation and the Imaging and Radiation Oncology Core, University of Cincinnati, Cincinnati.
  • University of California, San Francisco, San Francisco.
  • Alliance Statistics and Data Management Center, Mayo Clinic, Scottsdale, AZ.
  • University of Hawaii Cancer Center, Honolulu.

ORCID-Profile: Amylou C Dueck, Jonathan R Strosberg

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Exelixis

Zitieren

APA

Chan, J. A., Geyer, S., Zemla, T., Knopp, M. V., Behr, S., Pulsipher, S., Ou, F. S., Dueck, A. C., Acoba, J., Shergill, A., Wolin, E. M., Halfdanarson, T. R., Konda, B., Trikalinos, N. A., Tawfik, B., Raj, N., Shaheen, S., Vijayvergia, N., Dasari, A., …, & Meyerhardt, J. A. (2025). Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. New England Journal of Medicine, 392(7), 653-665. https://doi.org/10.1056/nejmoa2403991

Vancouver

Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, et al. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. New England Journal of Medicine. 2025;392(7):653-665. doi:10.1056/nejmoa2403991

BibTeX
@article{Chan2025,
  author = {Chan, Jennifer A and Geyer, Susan and Zemla, Tyler and Knopp, Michael V and Behr, Spencer and Pulsipher, Sydney and Ou, Fang-Shu and Dueck, Amylou C and Acoba, Jared and Shergill, Ardaman and Wolin, Edward M and Halfdanarson, Thorvardur R and Konda, Bhavana and Trikalinos, Nikolaos A and Tawfik, Bernard and Raj, Nitya and Shaheen, Shagufta and Vijayvergia, Namrata and Dasari, Arvind and Strosberg, Jonathan R and Kohn, Elise C and Kulke, Matthew H and O'Reilly, Eileen M and Meyerhardt, Jeffrey A},
  title = {Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {7},
  pages = {653--665},
  doi = {10.1056/nejmoa2403991}
}
Kostenlos starten →